Cited by 713Statistical Methods in Clinical TrialsColorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

The DOI matches its Crossref record; 33 of the 34 references it cites were found in a registry or an index.

Disease-Free Survival Versus Overall Survival As a Primary End Point for Adjuvant Colon Cancer Studies: Individual Patient Data From 20,898 Patients on 18 Randomized Trials

Sargent, Daniel J., Wieand, Harry S., Haller, Daniel G., Gray, Richard, Benedetti, Jacqueline K., Buyse, Marc, Labianca, Roberto, Seitz, Jean Francois, O'Callaghan, Christopher J., Francini, Guido, Grothey, Axel, O'Connell, Michael, Catalano, Paul J., Blanke, Charles D., Kerr, David, Green, Erin, Wolmark, Norman, Andre, Thierry, Goldberg, Richard M., De Gramont, Aimery·2005·Journal of Clinical Oncology

DOI 10.1200/jco.2005.01.6071

Open this paper in CoChat — free account

Abstract

PURPOSE: A traditional end point for colon adjuvant clinical trials is overall survival (OS), with 5 years demonstrating adequate follow-up. A shorter-term end point providing convincing evidence to allow treatment comparisons could significantly speed the translation of advances into practice. METHODS: Individual patient data were pooled from 18 randomized phase III colon cancer adjuvant clinical trials. Trials included 43 arms, with a pooled sample size of 20,898 patients. The primary hypothesis was that disease-free survival (DFS), with 3 years of follow-up, is an appropriate primary end point to replace OS with 5 years of follow-up. RESULTS: The recurrence rates for years 1 through 5 were 12%, 14%, 8%, 5%, and 3%, respectively. Median time from recurrence to death was 12 months. Eighty percent of recurrences were in the first 3 years; 91% of patients with recurrence by 3 years died before 5 years. Correlation between 3-year DFS and 5-year OS was 0.89. Comparing control versus experimental arms within each trial, the correlation between hazard ratios for DFS and OS was 0.92. Within-trial log-rank testing using both DFS and OS provided the same conclusion in 23 (92%) of 25 cases. Formal measures of surrogacy were satisfied. CONCLUSION: In patients treated on phase III adjuvant colon clinical trials, DFS and OS are highly correlated, both within patients and across trials. These results suggest that DFS after 3 years of median follow-up is an appropriate end point for adjuvant colon cancer clinical trials of fluorouracil-based regimens, although marginally significant DFS improvements may not translate into significant OS benefits.

Integrity signals

Registry

Crossref · 10.1200/jco.2005.01.6071

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer
André, T., Boni, C., Mounedji-Boudiaf, L., Navarro, M., Tabernero, J. M., Hickish, T., Topham, C., Zaninelli, M., Clingan, P. R., Bridgewater, J. A., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032709 · Cited by 3,694
A leisurely look at the bootstrap, the jackknife, and cross-validation
Efron, B., & Gong, G. (1983) · The American Statistician · doi:10.1080/00031305.1983.10483087 · Cited by 3,229
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
Saltz, L. B., Cox, J. V., Blanke, C. D., Rosen, L. S., Fehrenbacher, L., Moore, M. J., Maroun, J. A., Ackland, S. P., Locker, P. K., Pirotta, N., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431302 · Cited by 3,004
Levamisole and Fluorouracil for Adjuvant Therapy of Resected Colon Carcinoma
Moertel, C. G., Fleming, T. R., Macdonald, J. S., Haller, D. G., Laurie, J. A., Goodman, P. J., Ungerleider, J. S., Emerson, W. A., Tormey, D. C., Glick, J. H., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199002083220602 · Cited by 2,261
A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal Cancer
Goldberg, R. M., Sargent, D. J., Morton, R. F., Fuchs, C. S., Ramanathan, R. K., Williamson, S. K., Findlay, B., Pitot, H. C., & Alberts, S. R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.046 · Cited by 2,251
Surrogate endpoints in clinical trials: Definition and operational criteria
Prentice, R. L. (1989) · Statistics in Medicine · doi:10.1002/sim.4780080407 · Cited by 2,057
Surrogate End Points in Clinical Trials: Are We Being Misled?
Fleming, T. R., & DeMets, D. L. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-7-199610010-00011 · Cited by 1,651
American Society of Clinical Oncology Recommendations on Adjuvant Chemotherapy for Stage II Colon Cancer
Benson, A. B., Schrag, D., Somerfield, M. R., Cohen, A. M., Figueredo, A. T., Flynn, P. J., Krzyzanowska, M. K., Maroun, J. A., McAllister, P. K., Cutsem, E. V., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.063 · Cited by 1,438

Flagged first, then by citations

Show all 34 references

1 of the 34 references couldn’t be matched to a known paper.

Sorted by citations

Items 401–500 of 713

Colorectal cancer OncoGuia
Colorectal Cancer OncoGuia Group, Walsh, P. M., Borràs, J. M., Ferro, T., & Espinàs, J. A. (2010) · Clinical & Translational Oncology · doi:10.1007/s12094-010-0489-5 · Cited by 13
Adjuvant chemotherapy of colorectal cancer
Cunningham, D., & Starling, N. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61841-8 · Cited by 13
Effects of tyrosine kinase inhibitor E7080 and eNOS inhibitor L-NIO on colorectal cancer alone and in combination.
Altun, A., Temiz, T. K., Balcı, E., Polat, Z. A., & Turan, M. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.1000-9604.2013.10.10 · Cited by 13
Quantification of PFS Effect for Accelerated Approval of Oncology Drugs
Chen, C., & Sun, L. (2011) · Statistics in Biopharmaceutical Research · doi:10.1198/sbr.2011.09046 · Cited by 13
“In an adjuvant colon cancer setting, Sargent et al. (2005) estimated the regression slope”
BackgroundResultInfluential
Time to Initiation of Adjuvant Chemotherapy and Survival in Colorectal Cancer
Sargent, D. J., Grothey, A., & Gray, R. G. (2011) · JAMA · doi:10.1001/jama.2011.1319 · Cited by 13
Adjuvant chemotherapy for colon cancer: a confusing area!
Douillard, J., & Bennouna, J. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi413 · Cited by 13
You're Cured Till You're Not: Should Disease-Free Survival Be Used as a Regulatory or Clinical End Point for Adjuvant Therapy of Cancer?
Sobrero, A. F., Pastorino, A., & Zalcberg, J. R. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.01531 · Cited by 13
ctDNA to Guide Treatment of Colorectal Cancer: Ready for Standard of Care?
Puccini, A., Martelli, V., Pastorino, A., Sciallero, S., & Sobrero, A. F. (2023) · Current Treatment Options in Oncology · doi:10.1007/s11864-022-01048-x · Cited by 13
Establishment of a Nomogram-Based Prognostic Model (LASSO-COX Regression) for Predicting Progression-Free Survival of Primary Non-Small Cell Lung Cancer Patients Treated with Adjuvant Chinese Herbal Medicines Therapy: A Retrospective Study of Case Series
Luo, B., Yang, M., Han, Z., Que, Z., Luo, T., & Tian, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.882278 · Cited by 12
Assessment of the Addition of Oxaliplatin to Fluoropyrimidine-Based Adjuvant Chemotherapy in Patients With High-Risk Stage II Colon Cancer: An ACCENT Pooled Analysis
Chibaudel, B., Raeisi, M., Cohen, R., Yothers, G., Goldberg, R. M., Bachet, J., Wolmark, N., Yoshino, T., Schmoll, H., Kerr, R. S., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.24.00394 · Cited by 17
“4 Combinations including OX may confer additional bene ﬁ t in speci ﬁ c subgroups of patients with high-risk stage II CC. 5,6 In addition to stage, new clinical prognostic factors have been described, such as the site of tumor origin in the colon (tumor sidedness), age, and BMI.”
Influential
Colon cancer treatment and adherence to national guidelines: Does age still matter?
Jonker, J. M., Hamaker, M. E., Soesan, M., Tulner, C. R., & Kuper, I. M. J. A. (2012) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2011.12.003 · Cited by 13
Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials
Wang, X., Wang, X., Hodgson, L. C., George, S. L., Sargent, D. J., Foster, N. R., Ganti, A. K., Stinchcombe, T. E., Crawford, J., Kratzke, R. A., et al. (2017) · The Oncologist · doi:10.1634/theoncologist.2016-0121 · Cited by 12
MRI ‐Based Metastatic Nodal Number and Associated Nomogram Improve Stratification of Nasopharyngeal Carcinoma Patients: Potential Indications for Individual Induction Chemotherapy
Zhao, Q., Dong, A., Cui, C., Ou, Q., Ruan, G., Zhou, J. H., Tian, L., Liu, L., Ma, H., & Li, H. (2022) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.28435 · Cited by 12
“PFS was calculated until recurrence, death, and metastasis or censor of the last follow-up.(26,27)”
Method
Machine learning based prognostic model of Chinese medicine affecting the recurrence and metastasis of I-III stage colorectal cancer: A retrospective study in China
Tang, M., Gao, L., He, B., & Yang, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1044344 · Cited by 12
Evaluating the oncological safety of neoadjuvant chemotherapy in locally advanced colon carcinoma: a systematic review and meta-analysis of randomised clinical trials and propensity-matched studies
Davey, M. G., Amir, A. H., Ryan, O. K., Donnelly, M., Donlon, N. E., Regan, M., Meshkat, B., Nugent, E., Joyce, M., & Hogan, A. M. (2023) · International Journal of Colorectal Disease · doi:10.1007/s00384-023-04482-x · Cited by 12
“…LACC [19] • Disease-free survival: freedom from invasive disease recurrence or mortality due to any cause following treat-ment of primary LACC [19] Search strategy A predetermined electronic search was performed by two independent reviewers of the PubMed, Scopus, and Cochrane Library…”
BackgroundMethod
An information-theoretic approach to surrogate-marker evaluation with failure time endpoints
Pryseley, A., Tilahun, A., Alonso, A., & Molenberghs, G. (2010) · Lifetime Data Analysis · doi:10.1007/s10985-010-9185-6 · Cited by 12
Adjuvant therapy for colon cancer
Sun, W., & Haller, D. G. (2005) · Current Oncology Reports · doi:10.1007/s11912-005-0071-4 · Cited by 12
Comparison of KRAS/BRAF mutations between primary tumors and serum in colorectal cancer: Biological and clinical implications
Pu, X., Pan, Z., Huang, Y., TIAN, Y., Guo, H., Wu, L., HE, X., Chen, X., Zhang, S., & Lin, T. (2012) · Oncology Letters · doi:10.3892/ol.2012.963 · Cited by 12
“Chemotherapy prolongs the survival of patients with advanced CRC and high risk stage II patients (4,5).”
Background
Disease-Free Survival in Colon Cancer: Still Relevant After All These Years!
Grothey, A. F., de Gramont, A., & Sargent, D. J. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.4452 · Cited by 12
Statistical Considerations for the Next Generation of Clinical Trials
Wu, W., Shi, Q., & Sargent, D. J. (2011) · Seminars in Oncology · doi:10.1053/j.seminoncol.2011.05.014 · Cited by 11
1,4-dihydroxy quininib attenuates growth of colorectal cancer cells and xenografts and regulates the TIE-2 signaling pathway in patient tumours
Butler, C. T., Kennedy, S. A., Buckley, A. M., Doyle, R., Conroy, E., Gallagher, W. M., O'Sullivan, J. N., & Kennedy, B. N. (2019) · Oncotarget · doi:10.18632/oncotarget.26966 · Cited by 11
“According to the American Cancer Society ~40% of patients with colorectal cancer (CRC) are diagnosed with localised disease [1, 2].”
Background
Mid-transverse Location in Primary Colon Tumor: A Poor Prognostic Factor?
Zenger, S., Gürbüz, B., Can, U., Erginöz, E., Özata, İ. H., Kulle, C. B., Balık, E., & Buğra, D. (2021) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0000000000002083 · Cited by 11
Postoperative Fasting Blood Glucose Predicts Prognosis in Stage I-III Colorectal Cancer Patients Undergoing Resection
Xu, R., You, J., Li, F., & Yan, B. (2020) · Gastroenterology Research and Practice · doi:10.1155/2020/2482409 · Cited by 11
“The primary study endpoint was 3 years DFS, as defined in a previous study [21], and the last follow-up point occurred in October 2019.”
Method
A meta-analysis of the value of circulating tumor cells in monitoring postoperative recurrence and metastasis of colorectal cancer
Wu, J., Li, Z., Zou, J., Li, L., Cui, N., Hao, T., Yi, K., Yang, J., & Wu, Y. (2022) · PLoS ONE · doi:10.1371/journal.pone.0274282 · Cited by 11
“3 years after operation is the risk period for recurrence and metastasis of CRC [33].”
Background
Comparative effectiveness of postoperative chemotherapy among older patients with non-metastatic rectal cancer treated with preoperative chemoradiotherapy
Lund, J. L., Stürmer‎, T., & Sanoff, H. K. (2016) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2016.01.011 · Cited by 11
“Though long-term follow-up is immature, it seems unlikely that these results will markedly change given the close relationship between DFS and overall survival in colorectal cancer.(21) While expert guidelines from the National Comprehensive Cancer Network,(22) European Society of Medical Oncology,(23) and the Nationa…”
Background
Gold Nanostructures for Cancer Imaging and Therapy
Gao, Y., & Li, Y. (2015) · Springer series in biomaterials science and engineering · doi:10.1007/978-3-662-48544-6_2 · Cited by 11
Summary of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling
Holstein, S. A., Ye, J. C., Howard, A., Bhutani, M., Gormley, N. J., Hahn, T., Hillengaß, J., Krishnan, A. Y., Landgren, O., Munshi, N. C., et al. (2018) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2018.11.001 · Cited by 10
Statistical aspects in adjuvant and neoadjuvant trials for gastrointestinal cancer in 2020: focus on time-to-event endpoints
Saad, E. D., & Buyse, M. E. (2020) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000636 · Cited by 11
“The Adjuvant Colon Cancer Endpoints (ACCENT) Group used the preferred method of a metaanalysis of individual-patient data (IPD) to show that DFS – with a minimum of three years of median follow-up – can be considered a valid surrogate for overall survival in stage III colon cancer treated with adjuvant chemotherapy [4…”
BackgroundMethodInfluential
Lessons learnt from scoring adjuvant colon cancer trials and meta-analyses using the ESMO-Magnitude of Clinical Benefit Scale V.1.1
Knapen, D. G., Cherny, N. I., Zygoura, P., Latino, N. J., Douillard, J.-Y., Dafni, U. G., de Vries, E. G. E., & de Groot, D. J. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-000681 · Cited by 10
Current stage-specific chemotherapeutic options in colon cancer
Martin, M. J. (2005) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.5.4.695 · Cited by 11
Rapid Evolution in Colorectal Cancer: Therapy Now and Over the Next Five Years
de Gramont, A. (2005) · The Oncologist · doi:10.1634/theoncologist.10-90002-4 · Cited by 11
“Importantly, the 3-year DFS rate is highly correlated (r = 0.88) with survival at five years [ 11 ].”
BackgroundInfluential
Association of the benefit from gefitinib monotherapy with smoking status in Japanese patients with non-small-cell lung cancer
Hotta, K., Kiura, K., Takigawa, N., Fujiwara, Y., Tabata, M., Ueoka, H., & Tanimoto, M. (2008) · Lung Cancer · doi:10.1016/j.lungcan.2008.03.025 · Cited by 11
Simulation studies of surrogate endpoint validation using single trial and multitrial statistical approaches.
Lassere, M. N., Johnson, K. R., Hughes, M., Altman, D. G., Buyse, M. E., Galbraith, S., & Wells, G. (2007) · PubMed · Cited by 11
Disease-Free Survival at 2 and 3 Years is a Significant Early Surrogate Marker Predicting the 5-Year Overall Survival in Patients Treated with Radical Cystectomy for Urothelial Carcinoma of the Bladder: External Evaluation and Validation in a Cohort of Korean Patients
Kim, H. S., Jeong, C. W., Kwak, C. H., Kim, H. H., & Ku, J. H. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00246 · Cited by 10
Colorectal Cancer
Lawler, M., Johnston, B., Schaeybroeck, S. V., Salto‐Tellez, M., Wilson, R. H., Dunlop, M. G., & Johnston, P. G. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-47674-4.00074-8 · Cited by 10
Impact of Copula Directional Specification on Multi-Trial Evaluation of Surrogate End Points
Renfro, L. A., Shang, H., & Sargent, D. J. (2014) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543406.2014.920870 · Cited by 10
“…subsequently used to validate both disease-free survival (DFS) and progression-free survival (PFS) as surrogates for overall survival (OS) in the adjuvant colon cancer and advanced colorectal cancer settings, respectively (Sargent et al., 2005, 2007; Buyse et al., 2007; de Gramont et al., 2010).”
MethodResultInfluential
Phase III design: principles.
Buyse, M. E. (2016) · PubMed · doi:10.3978/j.issn.2304-3865.2014.08.05 · Cited by 14
“Until such time, some endpoints measured earlier than death (such as diseasefree survival in the adjuvant setting) have been shown to be excellent surrogates for survival (28).”
Background
Disease-free survival is not a surrogate endpoint for overall survival in adjuvant trials of pancreatic cancer: a systematic review of randomized trials
Petrelli, F., Tomasello, G., Ghidini, M., Lonati, V., Passalacqua, R., & Barni, S. (2017) · HPB · doi:10.1016/j.hpb.2017.07.005 · Cited by 10
Association of rs2282679 A>C polymorphism in vitamin D binding protein gene with colorectal cancer risk and survival: effect modification by dietary vitamin D intake
Zhu, Y., Wang, P., Zhai, G., Bapat, B. V., Savas, S., Woodrow, J. R., Campbell, P. T., Li, Y., Yang, N., Zhou, X., et al. (2018) · BMC Cancer · doi:10.1186/s12885-018-4026-1 · Cited by 10
“Thus, the DFS end point may be dominated by metastasis and recurrence rather than deaths from all causes [53]; the difference in outcomes may have affected the results.”
BackgroundResult
Approach to the Older Patient with Stage II/III Colorectal Cancer: Who Should Get Curative-Intent Therapy?
Ramsdale, E. E., Sanoff, H. K., & Muss, H. B. (2013) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbook_am.2013.33.163 · Cited by 10
Mining the ACCENT database: a review and update.
Renfro, L. A., Shi, Q., & Sargent, D. J. (2013) · PubMed · doi:10.3978/j.issn.2304-3865.2013.03.05 · Cited by 10
“In 2005, the first official ACCENT collaboration led by Dr. Daniel Sargent confirmed that DFS with median of 3 years of follow-up was an appropriate surrogate for OS with median of 5 years of follow-up, through the robust findings across several meta-analytic surrogacy analyses (5).”
Background
Contributions of meta-analyses based on individual patient data to therapeutic progress in colorectal cancer
Buyse, M. E. (2009) · International Journal of Clinical Oncology · doi:10.1007/s10147-009-0879-2 · Cited by 9
HER3 expression is correlated to distally located and low-grade colon cancer
Lédel, F., Stenstedt, K., Hallström, M., Ragnhammar, P., & Edler, D. (2016) · Acta Oncologica · doi:10.3109/0284186x.2015.1131334 · Cited by 9
“So why is HER3 expression in distal colon tumors prognostic regarding DFS but not for OS? DFS is an approved way of monitoring prognosis in colon cancer [13].”
Background
Validity of Adjuvant! Online in older patients with stage III colon cancer based on 2967 patients from the ACCENT database
Papamichael, D., Renfro, L. A., Matthaiou, C., Yothers, G., Saltz, L. B., Guthrie, K. A., Cutsem, E. V., Schmoll, H., Labianca, R., André, T., et al. (2016) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2016.07.002 · Cited by 9
Efficacy of aspirin for stage III colorectal cancer: a randomized double-blind placebo-controlled trial (JCOG1503C, EPISODE-III trial)
Miyamoto, K., Takashima, A., Mizusawa, J., Sato, Y., Shimada, Y., Katayama, H. G., Nakamura, K., Shibata, T., Fukuda, H., Shida, D., et al. (2019) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyz106 · Cited by 9
Biologic modulation of chemotherapy in patients with hepatic colorectal metastases: The role of anti‐VEGF and anti‐EGFR antibodies
Geva, R., Prenen, H., Topal, B., Aerts, R., Vannoote, J., & Cutsem, E. V. (2010) · Journal of Surgical Oncology · doi:10.1002/jso.21760 · Cited by 9
“The surrogate end point of DFS has been validated in the adjuvant setting [49] and in the metastatic setting PFS is emerging as an accepted alternative [50].”
Background
Adjuvant Therapy of Colon Cancer: Current Status and Future Developments
Morse, M. A. (2005) · Clinics in Colon and Rectal Surgery · doi:10.1055/s-2005-916283 · Cited by 9
Improving Efficiency in Clinical Trials Using Auxiliary Information: Application of a Multi-State Cure Model
Conlon, A. S. C., Taylor, J. M. G., & Sargent, D. J. (2015) · Biometrics · doi:10.1111/biom.12281 · Cited by 9
Using cure models and multiple imputation to utilize recurrence as an auxiliary variable for overall survival
Conlon, A. S. C., Taylor, J. M. G., Sargent, D. J., & Yothers, G. (2011) · Clinical Trials · doi:10.1177/1740774511414741 · Cited by 9
Evaluation of Three Definitions of Progression-free Survival in Preoperative Cancer Therapy (JCOG0801-A)
Nakamura, K., Shibata, T., Takashima, A., Yamamoto, S., & Fukuda, H. (2012) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hys122 · Cited by 9
“DFS after adjuvant chemotherapy in colon cancer (5) and PFS following first-line chemotherapy in advanced colorectal cancer (6,7) have proved to be good surrogate endpoints for OS in meta-analyses.”
Background
Clinicopathological Significance of the Expression of Estrogen Receptor-beta and Vascular Endothelial Growth Factor-A in Colorectal Cancer
Taggarshe, D., Lobocki, C. A., Silberberg, B. K., McKendrick, A., & Mittal, V. K. (2012) · The American Surgeon · doi:10.1177/000313481207801230 · Cited by 9
Disease-Free Survival Versus Overall Survival As a Primary End Point for Adjuvant Colon Cancer Studies: A Commentary
Abrams, J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.6186 · Cited by 9
“These advantages are balanced by several disadvantages: (1) use of OS as the primary end point may prolong evaluation of new therapies because of the long follow-up time required to obtain adequate information for assessment; (2) studies of long duration may be weakened by decreasing patient compliance over time and i…”
Background
The Hope for Today—The Promise for Tomorrow: Will Oncologists Meet the Challenge?
Benson, A. B. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.9838 · Cited by 9
Bayesian Adaptive Trial Design for a Newly Validated Surrogate Endpoint
Renfro, L. A., Carlin, B. P., & Sargent, D. J. (2011) · Biometrics · doi:10.1111/j.1541-0420.2011.01647.x · Cited by 8
“…I error, power, and surrogacy discrimination compared to a standard O’Brien– Fleming approach (O’Brien and Fleming, 1979), whereas Section 5 demonstrates the new trial design using patient-level data from actual trials and a historically validated endpoint in colon cancer (Sargent et al., 2005).”
BackgroundMethodInfluential
The Search for Surrogate Endpoints in Trials in Diffuse Large B-Cell Lymphoma: The Surrogate Endpoints for Aggressive Lymphoma Project
Sargent, D. J., Shi, Q., Flowers, C. R., Schmitz, N., Habermann, T. M., Flament, J., Fu, T., Coiffier, B., & on behalf of the SEAL group (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0177 · Cited by 8
Prediction by a multiparametric magnetic resonance imaging-based radiomics signature model of disease-free survival in patients with rectal cancer treated by surgery
Mao, J., Ye, W., Ma, W., Liu, J., Zhong, W., Yuan, H., Li, T., Guan, L., & Wu, D. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1255438 · Cited by 8
Möglichkeiten und Grenzen der onkologischen Chemotherapie bei alten Patienten
Wedding, U. (2010) · Der Internist · doi:10.1007/s00108-010-2601-x · Cited by 8
Postherapeutic follow-up of colorectal cancer patients treated with curative intent.
Mazilu, L., Ciufu, N., Gălan, M., Suceveanu, A., Suceveanu, A. P., Parepa, I. R., & Tofolean, D. E. (2012) · PubMed · Cited by 8
Pembrolizumab in the adjuvant treatment of melanoma: efficacy and safety
Nebhan, C. A., & Johnson, D. B. (2021) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1882856 · Cited by 8
The Clinical Significance of Mesenteric Lymphocytes in Human Colorectal Cancer
Wu, Z., Wang, F., Li, L., Yao, Y., Long, J., Luo, Q., Zhao, Z., Li, W., Cao, J., & Lian, Z. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.685577 · Cited by 8
Meeting on the FDA Draft Guidance on Patient-Reported Outcomes
Dueck, A. C., & Sloan, J. A. (2007) · Value in Health · doi:10.1111/j.1524-4733.2007.00268.x · Cited by 8
Association between time to disease progression end points and overall survival in patients with neuroendocrine tumors
Singh, S., Wang, X., & Law, C. H. L. (2014) · Gastrointestinal Cancer Targets and Therapy · doi:10.2147/gictt.s61671 · Cited by 8
Early stopping rules in oncology: Considerations for clinicians
Mukherjee, S. D., Goffin, J. R., Taylor, V. H., Anderson, K. K., & Pond, G. R. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.05.019 · Cited by 8
Laparoscopic surgery for rectal cancer: short-term benefits and oncologic outcomes using more than one technique
Larson, D. W., Boostrom, S. Y., Cima, R. R., Pemberton, J. H., Larson, D., & Dozois, E. J. (2010) · Techniques in Coloproctology · doi:10.1007/s10151-010-0577-0 · Cited by 8
Pancreatic Cancer and the Possibility of Long-term Survival
Ko, A. H. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.4869 · Cited by 8
Postoperative Quality Assessment Score Can Select Patients with High Risk for Locoregional Recurrence in Colon Cancer
Livadaru, C., Moscalu, M., Ghitun, F. A., Huluta, A. R., Terinte, C., Ferariu, D., Luncă, S., & Dimofte, G. M. (2022) · Diagnostics · doi:10.3390/diagnostics12020363 · Cited by 8
Two simple approaches for validating a binary surrogate endpoint using data from multiple trials
Baker, S. G. (2008) · Statistical Methods in Medical Research · doi:10.1177/0962280207081861 · Cited by 8
Is response rate increment obtained by molecular targeted agents related to survival benefit in the phase III trials of advanced cancer?
Tsujino, K., Shiraishi, J., Tsuji, T., Kurata, T., Kawaguchi, T., Kubo, A., & Takada, M. (2010) · Annals of Oncology · doi:10.1093/annonc/mdp588 · Cited by 8
“[4] and used in the decision to approve oxaliplatin for adjuvant colon cancer.”
Clinical Practice Guidelines in Oncology TM
Engstrom, P. F., Arnoletti, J. P., Benson, A. B., Chen, Y., Choti, M. A., Cooper, H. S., Covey, A. M., Dilawari, R. A., Early, D. S., Enzinger, P. C., et al. (2009) · Cited by 8
Functional Data Analysis using a Topological Summary Statistic: the Smooth Euler Characteristic TransformPreprint
Crawford, L. A., Monod, A., Chen, A., Mukherjee, S., & Rabadán, R. (2016) · arXiv (Cornell University) · Cited by 8
Targeted panel sequencing of pharmacogenes and oncodrivers in colorectal cancer patients reveals genes with prognostic significance
Heczko, L., Liška, V., Vyčítal, O., Fiala, O., Šůsová, S., Hlaváč, V., & Souček, P. (2024) · Human Genomics · doi:10.1186/s40246-024-00644-2 · Cited by 7
“Patients were divided according to RFS ≤ 3 years vs. > 3 years, which is an appropriate end point for adjuvant treatment of regimens based on 5-FU [25].”
Method
Nomograms for predicting recurrence of HER2 ‐positive breast cancer with different HR status based on ultrasound and clinicopathological characteristics
Zhang, X., Kong, H., Liu, X., Li, Q., Fang, X., Wang, J., Qin, Z., Hu, N., Tian, J., Cui, H., et al. (2024) · Cancer Medicine · doi:10.1002/cam4.70146 · Cited by 7
Estimating changes in overall survival using progression-free survival in metastatic breast and colorectal cancer
Bowater, R. J., Lilford, P., & Lilford, R. J. (2011) · International Journal of Technology Assessment in Health Care · doi:10.1017/s0266462311000201 · Cited by 7
“One of the main strengths of the approach that has been used is that relationships have been analyzed between actual survival times and not between the hazard ratios or relative risks for progression-free and overall survival as has been done in previous studies (1;3;4;5;7;10;12;13).”
Method
Laparoscopically Assisted vs Open Colectomy for Colon Cancer
Meta-Analysis, A. (2015) · Cited by 7
Clinical Trial Designs in Oncology
Korn, E. L., & Freidlin, B. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-47674-4.00018-9 · Cited by 7
Quality Standards for Surgery of Colorectal Peritoneal Metastasis After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
García-Fadrique, A., Estevan, R., & Ortí, L. S. (2021) · Annals of Surgical Oncology · doi:10.1245/s10434-021-10642-6 · Cited by 7
Surrogate endpoints for overall survival in early colorectal cancer from the clinician's perspective
Grothey, A. F. (2008) · Statistical Methods in Medical Research · doi:10.1177/0962280207081853 · Cited by 7
Defining stage III disease in colorectal cancer—aspects on treatment and evaluation of survival
Derwinger, K., Carlsson, G. U., & Ekman, T. (2010) · Journal of Surgical Oncology · doi:10.1002/jso.21567 · Cited by 7
“The DFS data and the timeframe when most recurrences occur do also support its use as a surrogate end-point to the 5-year survival [17].”
Background
Adjuvant Therapy for Localized High-Risk Renal Cell Carcinoma
Wood, E. L., Donin, N. M., & Shuch, B. M. (2020) · Urologic Clinics of North America · doi:10.1016/j.ucl.2020.04.007 · Cited by 7
Targeted Therapies as Adjuvant Treatment for Early-Stage Colorectal Cancer: First Impressions and Clinical Questions
Chibaudel, B., Tournigand, C., André, T., Larsen, A. K., & de Gramont, A. (2010) · Clinical Colorectal Cancer · doi:10.3816/ccc.2010.n.039 · Cited by 7
Time to first flare-up episode of GVHD can stratify patients according to their prognosis during clinical course of progressive- or quiescent-type chronic GVHD
Kim, D. H., Sohn, S. K., Baek, J. H., Lee, K.-H., Lee, J.-H., Choi, S.-J., & Shin, I.-H. (2007) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705806 · Cited by 7
Drug Insight: metastatic colorectal cancer—oral fluoropyrimidines and new perspectives in the adjuvant setting
Folprecht, G., & Köhne, C. (2005) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0353 · Cited by 7
“Since a recent large meta-analysis demonstrated that 3-year disease-free survival correlated closely with 5-year overall survival”
Background
Biological Therapy and Other Novel Therapies in Early-Stage Disease: Are They Appropriate?
Grothey, A. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1125 · Cited by 7
Adjuvant therapy for resected colon cancer 2017, including the IDEA analysis
Tang, M., Price, T. J., Shapiro, J. D., Gibbs, P., Haller, D. G., Arnold, D., Peeters, M., Segelov, E., Roy, A. C., Tebbutt, N. C., et al. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1444481 · Cited by 6
“Although 3-year DFS is a validated surrogate of OS, long-term OS data are still needed to confirm the robustness of the current results [37].”
Background
Surrogacy of Recurrence-free Survival for Overall Survival as an Endpoint of Clinical Trials of Perioperative Adjuvant Therapy in Hepatobiliary-pancreatic Cancers
Imamura, T., Ohgi, K., Mori, K. P., Ashida, R., Yamada, M., Otsuka, S., Uesaka, K., & Sugiura, T. (2023) · Annals of Surgery · doi:10.1097/sla.0000000000006084 · Cited by 7
Unnecessary Surgery Can Be Avoided by Judicious Use of PET/CT Scanning in Colorectal Cancer Patients
Amin, A., Reddy, A., Wilson, R. G., Jha, M., Miranda, S., & Amin, J. (2012) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-012-9391-4 · Cited by 6
The Impact of Chronic Kidney Disease in Patients With Locally Advanced Rectal Cancer Treated With Neoadjuvant Chemoradiation
Dudani, S., Marginean, H., Gotfrit, J., Tang, P. A., Monzon, J. G., Dennis, K. E. B., Kennecke, H. F., Powell, E. D., Babak, S., Cheung, W. Y., et al. (2021) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0000000000002116 · Cited by 6
A Radiomics Nomogram for Non-Invasive Prediction of Progression-Free Survival in Esophageal Squamous Cell Carcinoma
Yan, T., Liu, L., Yan, Z., Peng, M., Wang, Q., Zhang, S., Wang, L., Zhuang, X., Liu, H., Ma, Y., et al. (2022) · Frontiers in Computational Neuroscience · doi:10.3389/fncom.2022.885091 · Cited by 6
A hybrid approach to assess the structural impact of long noncoding RNA mutations uncovers key NEAT1 interactions in colorectal cancer
Aydın, E., Saus, E., Chorostecki, U., & Gabaldón, T. (2023) · IUBMB Life · doi:10.1002/iub.2710 · Cited by 6
Long-term outcomes of robot-assisted laparoscopic surgery versus conventional laparoscopic surgery for rectal cancer: single-center, retrospective, propensity score analyses
Mazaki, J., Ishizaki, T., Kuboyama, Y., Udo, R., Tago, T., Kasahara, K., Yamada, T., & Nagakawa, Y. (2024) · Journal of Robotic Surgery · doi:10.1007/s11701-024-01894-x · Cited by 6
“These long-term outcomes were similar to those reported previously [14, 20].”
BackgroundResult
Critères de substitution: méthodes de validation et état des lieux en cancérologie digestive
Méthy, N., Bedenne, L., & Bonnetain, F. (2009) · Bulletin du Cancer · doi:10.1684/bdc.2009.0858 · Cited by 6
Quantification of PFS Effect for Accelerated Approval of Oncology Drugs
Chen, C., & Sun, L. (2013) · Springer proceedings in mathematics & statistics · doi:10.1007/978-1-4614-7846-1_20 · Cited by 6
Systematic Review: Adjuvant Chemotherapy for Locally Advanced Rectal Cancer with respect to Stage of Disease
Hajibandeh, S., & Hajibandeh, S. (2015) · International Scholarly Research Notices · doi:10.1155/2015/710569 · Cited by 6
“significant DFS advantages may not translate into OS benefit [20].”
Does the decision in a validation process of a surrogate endpoint change with level of significance of treatment effect? A proposal on validation of surrogate endpoints
Sertdemır, Y., & Burgut, R. (2008) · Contemporary Clinical Trials · doi:10.1016/j.cct.2008.08.006 · Cited by 6
Cost-Effectiveness of Adjuvant Chemotherapy in the Treatment of Early-Stage Colon Cancer
Soni, A., & Chu, E. (2015) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2015.05.002 · Cited by 6
“Only in multivariate analyses did the long-term followup of X-ACT data show a statistically significant improvement in OS.18 In terms of actual drug cost, capecitabine is more expensive than 5-FU, but drug administration costs and costs of treating adverse effects ultimately drive up 5-FU costs, according to some of t…”
Influential
Factors associated with short recurrence-free survival in completely resected colon cancer
Alnimer, Y. M., Ghamrawi, R., Aburahma, A., Salah, S. H., Ríos‐Bedoya, C. F., & Katato, K. (2017) · Journal of Community Hospital Internal Medicine Perspectives · doi:10.1080/20009666.2017.1407210 · Cited by 6
“chemotherapy [15], we decided to measure RFS as a primary outcome.”
Method
The outcome of intravenous and inhalation anesthesia after pancreatic cancer resection: a retrospective study
Ren, J., Wang, J., Chen, J., Ma, Y., Yang, Y., Wei, M., Wang, Y., & Wang, L. (2022) · BMC Anesthesiology · doi:10.1186/s12871-022-01703-8 · Cited by 6
“DFS might replace OS as a surrogate endpoint for cancer patients [27], but it had not been Fig.”
Background
North Central Cancer Treatment Group—Achievements and Perspectives
Grothey, A. F., Adjei, A. A., Alberts, S. R., Perez, E. A., Jaeckle, K. A., Loprinzi, C. L., Sargent, D. J., Sloan, J. A., & Buckner, J. C. (2008) · Seminars in Oncology · doi:10.1053/j.seminoncol.2008.07.006 · Cited by 6
Capecitabine: the new generation of fluoropyrimidines in colorectal cancer
Iqbal, S., & Lenz, H. (2004) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.4.6.947 · Cited by 6
Transportability Methods for Time-to-Event Outcomes: Application in Adjuvant Colon Cancer Trials
Zuo, S., Josey, K., Raghavan, S., Yang, F., Juarez‐Colunga, E., & Ghosh, D. (2022) · JCO Clinical Cancer Informatics · doi:10.1200/cci.22.00088 · Cited by 5

Authors: Sargent, D. J., Wieand, H. S., Haller, D. G., Gray, R., Benedetti, J. K., Buyse, M., Labianca, R., Seitz, J. F., O'Callaghan, C. J., Francini, G., Grothey, A., O'Connell, M., Catalano, P. J., Blanke, C. D., Kerr, D., Green, E., Wolmark, N., Andre, T., Goldberg, R. M., & De Gramont, A.
Affiliations: University of Siena (IT)
From the North Central Cancer Treatment Group, Mayo Clinic, Rochester, MN; National Surgical Adjuvant Breast and Bowel Project Statistical Center and Operations Office, Pittsburgh; Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; QUASAR Collaborative Group, Birmingham and Oxford, United Kingdom; Southwest Oncology Group Statistical Center, Seattle, WA; International Drug Development Institute, Brussels, Belgium; Ospedali Riuniti, Bergamo; University of Siena, Siena, Italy; University...
ORCID: Sargent, Daniel J.
Haller, Daniel G.
Gray, Richard
Buyse, Marc
Labianca, Roberto
Grothey, Axel
Catalano, Paul J.
Blanke, Charles D.
Kerr, David
Green, Erin
Wolmark, Norman
Goldberg, Richard M.
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2005-12-01
Volume: 23
Issue: 34
Pages: 8664-8670
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2005.01.6071
OpenAlex: W2172116130
Cited by: 713
References: 34
Citations by year: 2026: 19 · 2025: 14 · 2024: 19 · 2023: 20 · 2022: 34 · 2021: 32 · 2020: 27 · 2019: 20 · 2018: 24 · 2017: 30 · 2016: 26 · 2015: 40 · 2014: 36 · 2013: 40 · 2012: 44
FWCI: 48.43
Type: journal article
Language: en
Open access: closed
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
Document Server@UHasselt (UHasselt) (submittedVersion)
University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
Use Siena air (University of Siena) (submittedVersion)
Funders: National Cancer Institute ((CA-25224, U10CA025224)
Topics: Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
Keywords: colon cancer, adjuvant chemotherapy, disease-free survival, overall survival, primary endpoint, surrogate endpoints, hazard ratio correlation, recurrence, individual patient data pooling
MeSH terms: Aged, Antineoplastic Combined Chemotherapy Protocols, Colonic Neoplasms, Combined Modality Therapy, Female, Follow-Up Studies, Humans, Male, Middle Aged, Neoplasm Recurrence, Local, Regression Analysis, Randomized Controlled Trials as Topic, Treatment Outcome, Chemotherapy, Adjuvant, Disease-Free Survival

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Disease-Free Survival Versus Overall Survival As a Primary End Point for Adjuvant Colon Cancer Studies: Individual Patient Data From 20,898 Patients on 18 Randomized Trials

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks